Shengtai Pharmaceutical Schedules 2009 Third Quarter Financial Results and Conference Call

WEIFANG, Shandong, China, May 13 /PRNewswire-Asia/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it will issue financial results for the three months ended March 31, 2009 after the close of the stock market on Thursday, May 14, 2009. Management will conduct a conference call on Friday, May 15, 2009 at 8:30 A.M. Eastern Daylight Time to discuss these results. A question and answer session will follow management’s presentation.

Ms. Yiru Melody Shi (Chief Financial Officer), and Ms. Michelle Wang (Investor Relations Manager) will be the primary speakers on the call.

A live webcast of the conference call will be available on the Investor Relations page of Shengtai Pharmaceutical’s web site at http://www.shengtaipharmaceutical.com . Please visit the Web site at least 15 minutes early to register for the webcast and download any necessary audio software.

To participate, please call the following numbers ten minutes before the call start time:

Phone Number + 1 (877) 407-9205 (North America)

Phone Number + 1 (201) 689-8054 (International)

A replay of the call will be available through Thursday, May 21, 2009, at 11:59 P.M. Eastern Daylight Time. For the replay, please call:

Phone Number +1 (877) 660-6853 (North America)

Phone Number +1 (201) 612-7415 (International)

Account Number: 286

Conference ID Number: 323305

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes. It also manufactures and supplies glucose and cornstarch products to the food, beverage and industrial production industries in China.

Forward-looking Statements

Certain statements made in this news release, may contain forward-looking statements concerning the Company’s business and products. These statements include, without limitation, statements regarding our ability to prepare the Company for growth, future increases in market demand, possible increases in our market share and predictions and guidance relating to the Company’s future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company’s products, changes to government regulations, risk associated with operation of the Company’s new facilities, risk associated with large-scale implementation of the Company’s business plan, the ability to attract new customers, ability to increase our products’ applications, cost of raw materials, downturns in the Chinese and world economy, and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations.

For more information, please contact:

Shengtai Pharmaceutical, Inc.

Ms. Yiru Melody Shi

Chief Financial Officer

Email: shengtaicfo@hotmail.com

Grayling

Eddie Cheung

Investor Relations

Tel: +1-646-284-9414

Email: eddie.cheung@us.grayling.com

Related stocks: OTC:SGTI